Pasar al contenido principal

ONCOPROTEINAS DE LA FAMILIA VAV: REGULACION, FUNCIONES PATOFISIOLOGICAS Y POTENCIAL TERAPEUTICO

SAF2015-64556-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges

  • Bustelo, Xosé R.
  • Crespo, Piero
  • Fernández-Pisonero, Isabel
  • Rodríguez-Fdez, Sonia
Deregulated RAS signaling is associated with increasing numbers of congenital diseases usually referred to as RASopathies. The spectrum of genes and mutant alleles causing these diseases has been significantly expanded in recent years. This progress has triggered new challenges, including the origin and subsequent selection of the mutations driving these diseases, the specific pathobiological programs triggered by those mutations, the type of correlations that exist between the genotype and the clinical features of patients, and the ancillary genetic factors that influence the severity of the disease in patients. These issues also directly impinge on the feasibility of using RAS pathway drugs to treat RASopathy patients. Here, we will review the main developments and pending challenges in this research topic., The authors wish to apologize to scientists who have not been cited in this work due to space constraints. XRB work is supported by grants from the Castilla-León Government (CSI049U16), Spanish Ministry of Economy and Competitiveness (SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society against Cancer (GC16173472GARC). PC work is supported by grants from both the Spanish Ministry of Economy and Competitiveness (SAF-2015 63638R) and the Spanish Society against Cancer (GCB141423113). Funding from Spanish national and regional governments to both XRB and PC is partially contributed by the European Regional Development Fund.